These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling. Li Y; Zhang D; Kong L; Shi H; Tian X; Gao L; Liu Y; Wu L; Du B; Huang Z; Liang C; Wang Z; Yao R; Zhang Y Exp Cell Res; 2018 Sep; 370(1):78-86. PubMed ID: 29902536 [TBL] [Abstract][Full Text] [Related]
4. Exacerbated cardiac fibrosis induced by β-adrenergic activation in old mice due to decreased AMPK activity. Wang J; Song Y; Li H; Shen Q; Shen J; An X; Wu J; Zhang J; Wu Y; Xiao H; Zhang Y Clin Exp Pharmacol Physiol; 2016 Nov; 43(11):1029-1037. PubMed ID: 27389807 [TBL] [Abstract][Full Text] [Related]
5. AMP-activated protein kinase in the control of cardiac metabolism and remodeling. Horman S; Beauloye C; Vanoverschelde JL; Bertrand L Curr Heart Fail Rep; 2012 Sep; 9(3):164-73. PubMed ID: 22767403 [TBL] [Abstract][Full Text] [Related]
7. Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells. Chang W; Zhang M; Meng Z; Yu Y; Yao F; Hatch GM; Chen L Eur J Pharmacol; 2015 Dec; 769():55-63. PubMed ID: 26522928 [TBL] [Abstract][Full Text] [Related]
8. Failure to sense energy depletion may be a novel therapeutic target in chronic kidney disease. Kikuchi H; Sasaki E; Nomura N; Mori T; Minamishima YA; Yoshizaki Y; Takahashi N; Furusho T; Arai Y; Mandai S; Yamashita T; Ando F; Maejima Y; Isobe K; Okado T; Rai T; Uchida S; Sohara E Kidney Int; 2019 Jan; 95(1):123-137. PubMed ID: 30455054 [TBL] [Abstract][Full Text] [Related]
9. AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Sung MM; Zordoky BN; Bujak AL; Lally JS; Fung D; Young ME; Horman S; Miller EJ; Light PE; Kemp BE; Steinberg GR; Dyck JR Cardiovasc Res; 2015 Jul; 107(2):235-45. PubMed ID: 26023060 [TBL] [Abstract][Full Text] [Related]
10. Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy? Li T; Jiang S; Yang Z; Ma Z; Yi W; Wang D; Yang Y Cell Mol Life Sci; 2017 Apr; 74(8):1413-1429. PubMed ID: 27815596 [TBL] [Abstract][Full Text] [Related]
11. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Chan AY; Dyck JR Can J Physiol Pharmacol; 2005 Jan; 83(1):24-8. PubMed ID: 15759047 [TBL] [Abstract][Full Text] [Related]
12. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. Shimano M; Ouchi N; Shibata R; Ohashi K; Pimentel DR; Murohara T; Walsh K J Mol Cell Cardiol; 2010 Aug; 49(2):210-20. PubMed ID: 20206634 [TBL] [Abstract][Full Text] [Related]
13. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Beauloye C; Bertrand L; Horman S; Hue L Cardiovasc Res; 2011 May; 90(2):224-33. PubMed ID: 21285292 [TBL] [Abstract][Full Text] [Related]
14. CHIP protects against cardiac pressure overload through regulation of AMPK. Schisler JC; Rubel CE; Zhang C; Lockyer P; Cyr DM; Patterson C J Clin Invest; 2013 Aug; 123(8):3588-99. PubMed ID: 23863712 [TBL] [Abstract][Full Text] [Related]
15. Myostatin regulates energy homeostasis in the heart and prevents heart failure. Biesemann N; Mendler L; Wietelmann A; Hermann S; Schäfers M; Krüger M; Boettger T; Borchardt T; Braun T Circ Res; 2014 Jul; 115(2):296-310. PubMed ID: 24807786 [TBL] [Abstract][Full Text] [Related]
16. Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice. Yang J; Mou Y; Wu T; Ye Y; Jiang JC; Zhao CZ; Zhu HH; Du CQ; Zhou L; Hu SJ Cardiovasc Res; 2013 Mar; 97(3):490-9. PubMed ID: 23180723 [TBL] [Abstract][Full Text] [Related]
17. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo. Mummidi S; Das NA; Carpenter AJ; Kandikattu H; Krenz M; Siebenlist U; Valente AJ; Chandrasekar B J Mol Cell Cardiol; 2016 Sep; 98():95-102. PubMed ID: 27423273 [TBL] [Abstract][Full Text] [Related]
18. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. Li HL; Yin R; Chen D; Liu D; Wang D; Yang Q; Dong YG J Cell Biochem; 2007 Apr; 100(5):1086-99. PubMed ID: 17266062 [TBL] [Abstract][Full Text] [Related]
19. AMPK signalling and the control of substrate use in the heart. Nagendran J; Waller TJ; Dyck JR Mol Cell Endocrinol; 2013 Feb; 366(2):180-93. PubMed ID: 22750050 [TBL] [Abstract][Full Text] [Related]